The Patent Finder

Inventiva

13 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 20, 2027
    The maintenance fee for Ppar Compounds for Use in the Treatment of Fibrotic Diseases (US 10,383,858) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma (US 10,414,739) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 1 fee due May 28, 2027
    The maintenance fee for Crystal Form of Lanifibranor, Preparation Method Therefor, and Use Thereof (US 11,827,630) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,795,297Indole Compounds, Method of Preparing Them and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 7,652,0325-Thioxylopyranose compounds
In force
 · USPTO record
In forceUSPTO record
US 8,436,040Method of Treating Conditions Involving Ppar-Receptors with Indole Compounds
In force
 · High confidence
In forceHigh confidence
US 9,561,246Use of Odiparcil in the treatment of a mucopolysaccharidosis
In force
 · USPTO record
In forceUSPTO record
US 10,092,540Method of treatment of a mucopolysaccharidosis
In force
 · USPTO record
In forceUSPTO record
US 10,052,311Ppar Compounds for Use in the Treatment of Fibrotic Diseases
In force
 · High confidence
In forceHigh confidence
US 10,383,858Ppar Compounds for Use in the Treatment of Fibrotic Diseases
In force
 · High confidence
In forceHigh confidence
US 10,414,739Compounds as inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma
In force
 · USPTO record
In forceUSPTO record
US 11,504,380Method of Treatment of Cirrhosis
In force
 · High confidence
In forceHigh confidence
US 11,999,758Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer
In force
 · USPTO record
In forceUSPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 8 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 1 abandoned · 3 no status recorded

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/194,878Apr 30, 2025No status recorded
19/080,283Methods and monitoring of treatment with lanifibranorMar 14, 2025Pending
18/735,392Non-Invasive Monitoring of Liver Disease TreatmentJun 6, 2024Pending
18/735,373Non-Invasive Monitoring of Liver Disease TreatmentJun 6, 2024Pending
18/854,287Crystalline Form of LanifibranorApr 4, 2023Pending
18/037,123Combination Therapy for the Treatment of a Liver DiseaseNov 16, 2021Abandoned
16/499,912Apr 6, 2018No status recorded
15/120,579Feb 19, 2015No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited